• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Exicure

Biotech

Exicure exodus: CEO resigns, CTO exits, 3 board members depart

Exicure becomes a shell of its former self with exits of CEO, chief medical officer, chief technology officer and three board members amid staff cuts.
Kyle LaHucik Feb 4, 2022 9:58am

Ipsen commits up to $1B to Exicure for two rare neuro assets

Aug 2, 2021 10:41am

Northwestern U's novel RNA drug shows promise in brain cancer

Mar 10, 2021 2:00pm

Allergan pays Exicure $25M to discover hair loss drugs

Nov 14, 2019 7:00am

Exicure plans checkpoint combo after TLR9 drug clears early test

Sep 20, 2018 7:25am

Immune cell compound could treat multiple autoimmune diseases

Apr 20, 2018 2:01pm
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy